Loading
Epigenetics and DNA Methylation / Cancer Cells and Metastasis / Breast Cancer Treatment Studies · Journal article
Biomedicines · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes epigenetic mechanisms proposed to drive therapy resistance in triple-negative breast cancer and discusses putative biomarkers and drug targets. The review frames epigenetic plasticity as a conceptual model but does not present original empirical evidence, controlled trials, or comparative outcome data to evaluate the clinical utility or efficacy of any specific intervention.
Journal article. Triple-negative breast cancer cells and tumors; no specific clinical cohort enrolled or studied..
TNBC shows initial chemotherapy sensitivity but develops adaptive resistant cell states through epigenetic reprogramming rather than fixed genetic mutations alone. Epigenetic mechanisms implicated include DNA methylation, histone modifications, BET/BRD4 regulation, EZH2-mediated repression, SWI/SNF remodeling, and non-coding RNA networks. Proposed epigenetic biomarkers include DNA methylation signatures, circulating epigenetic markers, chromatin-accessibility profiles, and single-cell epigenomic approaches.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize this as a state-of-knowledge synthesis rather than actionable evidence for practice change. While the conceptual framework highlights epigenetic plasticity as a resistance mechanism, therapeutic recommendations are theoretical and require validation in rigorously designed clinical trials before implementation.
This is a narrative review synthesizing mechanistic concepts and therapeutic rationales without reporting primary empirical findings, clinical trial data, or comparative evidence from original research.
Clinicians should recognize this as a state-of-knowledge synthesis rather than actionable evidence for practice change. While the conceptual framework highlights epigenetic plasticity as a resistance mechanism, therapeutic recommendations are theoretical and require validation in rigorously designed clinical trials before implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is an aggressive and clinically heterogeneous breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 overexpression, limited targeted treatment options, early relapse, and frequent development of therapy resistance. Although TNBC often shows initial sensitivity to chemotherapy, durable responses are commonly undermined by the emergence of adaptive resistant cell states rather than solely by fixed genetic mutations. This review synthesizes the role of epigenetic plasticity as a central mechanism that enables TNBC cells to dynamically reprogram transcriptional identity, survive therapeutic stress, and transition between epithelial, mesenchymal, stem-like, immune-evasive, and drug-tolerant persister phenotypes. Key epigenetic mechanisms include aberrant DNA methylation, histone acetylation and methylation, BET/BRD4-dependent transcriptional regulation, EZH2-mediated repression, SWI/SNF-dependent chromatin remodeling, non-coding RNA networks, and three-dimensional genome reorganization. These processes regulate tumor suppressor silencing, DNA-damage repair, epithelial–mesenchymal plasticity, cancer stem-cell maintenance, metabolic adaptation, immune-checkpoint regulation, and minimal residual disease. The review also highlights the translational relevance of epigenetic biomarkers, including DNA methylation signatures, circulating epigenetic markers, chromatin-accessibility profiles, and single-cell epigenomic approaches for diagnosis, prognosis, therapy prediction, and monitoring resistance evolution. Finally, therapeutic strategies targeting epigenetic plasticity are discussed, including DNMT, HDAC, BET, EZH2, KDM, and LSD1 inhibitors, with emphasis on rational combination approaches involving chemotherapy, PARP inhibitors, immunotherapy, and metabolic targeting. Overall, epigenetic plasticity represents both a major driver of TNBC resistance and a therapeutically exploitable vulnerability, provided those future strategies account for tumor heterogeneity, adaptive cell-state transitions, biomarker-guided patient selection, and combination-based treatment design.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.